Showing 3601-3610 of 6412 results for "".
- Alemtuzumab Highly Effective in CTCL Without Papular History: Analysishttps://practicaldermatology.com/news/study-alemtuzumab-highly-effective-in-ctcl-without-papular-history/2474209/A new analysis suggests the absence of papules, plaques, and tumors (PPT) in cutaneous T-cell lymphoma (CTCL) may predict favorable clinical outcomes with low dose alemtuzumab (LDA) therapy. In a retrospective cohort study
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- Study: Strontium May Help Alleviate Pruritus for HS Patientshttps://practicaldermatology.com/news/Study-Strontium-May-Help-Alleviate-Pruritus-HS-Patients/2474128/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to a new research article published in the Journal of Clinical and Aesthetic Dermatology. In a prospective, open-label, real-world study involving 50 part
- Outpatient Palliative Care Results in More Positive Experience for HS Patientshttps://practicaldermatology.com/news/empathy-and-expertise-define-positive-palliative-care-experiences-for-hs-patients/2474029/Individuals with hidradenitis suppurativa (HS) who receive outpatient palliative care (PC) reported significant improvements in wellbeing, according to findings published in Archives of Dermatological Research.
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- Secukinumab Reduces Erosions in Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/secukinumab-reduces-erosions-in-psoriatic-arthritis-patients/2471713/Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial. The study evaluated the impact of the I
- Interim Analysis: Dupilumab Reduces Itch, Pain in Ichthyosis and EBhttps://practicaldermatology.com/news/Interim-Analysis-Dupilumab-Reduces-Itch-Pain-Ichthyosis-EB/2471652/Dupilumab reduced both itch and pain in congenital ichthyosis and epidermolysis bullosa (EB), with no new safety issues, in an interim analysis presented during the late-breakers sessions at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Medical student
- Analysis: Strontium Cream Reduces Pruritus in Hidradenitis Suppurativa Patientshttps://practicaldermatology.com/news/analysis-strontium-cream-reduces-pruritus-in-hidradenitis-suppurativa-patients/2471630/Topical strontium cream significantly alleviates pruritus in patients with hidradenitis suppurativa (HS), according to a recent study published in the Journal of Clinical and Aesthetic Dermatology.
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trialhttps://practicaldermatology.com/news/iconic-lead-icotrokinra-clears-almost-half-of-psoriasis-patients-in-phase-3-trial/2471543/Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Dermatology Annual Meeting. The